J A Diazgranados-Sanchez1,2,3, J L Mejia-Fernandez4,3, L S Chan-Guevara4,5, M H Valencia-Artunduaga2,3, J L Costa6. 1. Universidad de Buenos Aires, Buenos Aires, Argentina. 2. Universidad del Valle, Cali, Colombia. 3. Neurologos de Occidente SAS, Cali, Colombia. 4. Universidad Libre Seccional de Cali, Cali, Colombia. 5. Staedtisches Klinikum Braunschweig, Braunschweig, Alemania. 6. Pritzker School of Medicine. University of Chicago, Chicago, Illinois, EE.UU.
Abstract
INTRODUCTION: Ivermectin, a 22'23 dihydro derivative of avermectins beta-1a, is a highly effective veterinary and human anti parasitic, used to treat endoparasites of difficult control such as filariasis and onchocerciasis, with a median plasma life of at least of 16 hours. The recommended therapeutic doses range from 0.05 to 0.40 mg/kg, without undesirable effects or risk to human life. It went from being a great success in animal health to its application in humans, where it has had great impact. Studies in basic sciences have shown that ivermectin has anticonvulsive effects in different epileptic animal models, where five different mechanisms of action have been described. PATIENTS AND METHODS: Descriptive, prospective observational study, performed between 2013 and 2015, with 32 refractory epileptic patients, who received ivermectin as an a dose of adjunctive treatment of 10 mg/day three or seven times a week, controlled every three months, followed by 12-24 months, without withdrawal of anticonvulsant medications that they received previously. RESULTS: Progressively, patients entered into crisis control, at the end of the programmed follow-up period, the total percentage of crisis reduction was 97%, of which 57% did not return to crisis from the beginning of treatment, all patients being free of crisis according to International League Against Epilepsy criteria. CONCLUSION: Ivermectin has been useful as an adjuvant, achieving a significant decrease in seizures in this group of drug resistant patients.
INTRODUCTION:Ivermectin, a 22'23 dihydro derivative of avermectins beta-1a, is a highly effective veterinary and human anti parasitic, used to treat endoparasites of difficult control such as filariasis and onchocerciasis, with a median plasma life of at least of 16 hours. The recommended therapeutic doses range from 0.05 to 0.40 mg/kg, without undesirable effects or risk to human life. It went from being a great success in animal health to its application in humans, where it has had great impact. Studies in basic sciences have shown that ivermectin has anticonvulsive effects in different epileptic animal models, where five different mechanisms of action have been described. PATIENTS AND METHODS: Descriptive, prospective observational study, performed between 2013 and 2015, with 32 refractory epilepticpatients, who received ivermectin as an a dose of adjunctive treatment of 10 mg/day three or seven times a week, controlled every three months, followed by 12-24 months, without withdrawal of anticonvulsant medications that they received previously. RESULTS: Progressively, patients entered into crisis control, at the end of the programmed follow-up period, the total percentage of crisis reduction was 97%, of which 57% did not return to crisis from the beginning of treatment, all patients being free of crisis according to International League Against Epilepsy criteria. CONCLUSION:Ivermectin has been useful as an adjuvant, achieving a significant decrease in seizures in this group of drug resistant patients.
Authors: Alfred Dusabimana; Solomon Tsebeni Wafula; Stephen Jada Raimon; Joseph Nelson Siewe Fodjo; Dan Bhwana; Floribert Tepage; Gasim Abd-Elfarag; An Hotterbeekx; Steven Abrams; Robert Colebunders Journal: Pathogens Date: 2020-12-31